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Abstract The study aimed to compare the kinetics of two
novel combination drug products for Female Sexual
Interest/Arousal Disorder (FSIAD). Thirteen women
received testosterone via the sublingual route followed
2.5 hours later by a buspirone tablet, versus a single
combination tablet swallowed at once. The first clinical
prototype consisted of a sublingual solution containing
testosterone (0.5 mg) complexed with cyclodextrin and a
tablet containing 10 mg buspirone, in a gelatin capsule to
ensure blinding during the clinical studies. The innovative
fixed-combination tablet consists of an inner-core compo-
nent of 10 mg buspirone coated with a polymeric time-
delay coating and an outer polymeric coating containing
testosterone with hydroxypropyl-beta cyclodextrin. We
observed an immediate testosterone pulse absorption from
both formulations. We also demonstrated that there was
adequate absorption of buspirone ([80 % relative to the
conventional tablet) and a time delay in release of buspi-
rone of 3.3 hours, close to the 3.0 hours of the reference
formulation that showed clinical efficacy in early proof-of-
principle studies. The newly developed combination tablet
fulfils its design criteria and is a convenient tablet for
further clinical studies in FSIAD.
1 Introduction
Human sexual behavior is extensively studied in biology,
medicine and psychology, but so far there is limited suc-
cess in the development of drugs for the treatment of sexual
dysfunction in women. Low sexual desire, with or without
sexual arousal problems, is the most common sex-related
complaint reported by women [1–3]. As a result, many
women suffer from sexual dissatisfaction, which often
negatively interferes with psychological well-being [4].
This has been classified as a clinical condition, referred to
as Hypoactive Sexual Desire Disorder (HSDD) [5] or, as
recently renamed, Female Sexual Interest/Arousal Disorder
(FSIAD) [6]. We have developed two new promising
potential treatments for HSDD/FSIAD which are based on
the premise that this disorder can have (at least) two dif-
ferent causes [7, 8].
For women who have a low sensitivity to sexual cues,
Lybrido is indicated. Lybrido is the combination of sub-
lingual testosterone and a phosphodiesterase type 5 (PDE-5)
inhibitor, which is absorbed from the gastro-intestinal tract.
Sublingual testosterone (0.5 mg) produces an increase in
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sexual motivation and desire in sexually functional women,
about 4 hours after its peak plasma levels (time to maxi-
mum concentration [Tmax] = 15 min) [9]. The testosterone
and the PDE-5 inhibitor are released in such a timeframe
that the peak plasma concentration of the PDE-5 inhibitor
coincides with the 4-hour delay in behavioral effects of the
testosterone. In women with low sensitivity to sexual cues,
this combination showed superiority over placebo in
increasing sexual satisfaction [7, 10]. For women who have
a dysfunctional activation of sexual inhibitory mechanisms
during sexual stimulation, Lybridos is developed. Lybridos
is the combination of sublingual testosterone and a 5-HT1A
receptor agonist (buspirone), released in such a timeframe
that the pharmacological effects of the 5-HT1A receptor
agonist coincide with the behavioral window induced by the
testosterone administration [8]. This combination in women
with dysfunctional activation of sexual inhibitory mecha-
nisms increased sexual satisfaction compared with placebo
[8]. In previous clinical trials, the two components (sub-
lingual testosterone in combination with a PDE-5 inhibitor
or 5-HT1A receptor agonist) were administered separately;
however, these components have been developed into one
single combination tablet in recent phase IIb trials.
Both products are intended for use on a ‘per need’ (i.e.,
not continuous or chronic) basis before anticipated sexual
activity. Studies performed by various researchers have
clearly indicated a time lag of about 3–4 hours in the
pharmacodynamics effect of sublingual testosterone on
genital arousal in women and other cognitive and affective
functions [9, 11–23]. Therefore, either the PDE5 inhibitor
(Lybrido) or (5-HT1a) receptor agonist (Lybridos) com-
ponent needs to be administered approximately 2–3 hours
after administering the testosterone. In the above-men-
tioned clinical studies, this was obtained by administering
the testosterone sublingually as a solution, followed
2.5 hours later by a PDE-5 inhibitor (sildenafil) or a
5-HT1A receptor agonist (buspirone) as a tablet (to ensure
blinding, the tablet was administered in a gelatin capsule),
thus creating overlapping peaks in effect of testosterone
and sildenafil or buspirone. Because this kind of adminis-
tration is not suitable and rather cumbersome for daily use
in practice, we developed a single oral combination tablet
that will deliver testosterone sublingually and, approxi-
mately 2.5 hours later in the gastro-intestinal tract, the
sildenafil or buspirone component, allowing women with
FSIAD to take just one single tablet 3–6 hours before the
anticipated sexual activity.
The objective of this study was to see if the pharma-
cokinetic profile of testosterone given sublingually fol-
lowed 2.5 hours later by a tablet of buspirone
(administered in a gelatin capsule) mimics the pharmaco-
kinetic properties of the newly developed single combi-
nation tablet as described above. The results of the
pharmacokinetic study of the combination of testosterone
and sildenafil will be described separately.
At frequent time points, plasma samples were taken and
the following pharmacokinetic parameters were deter-
mined: the time to maximum concentration (Tmax), half-life
(T), maximum concentration (Cmax), and area under the
curve (AUC) for total testosterone, free testosterone,
buspirone, and buspirone’s main metabolite (1-(2-pyri-
midinyl)-piperazine) for each formulation.
2 Methods
2.1 Study Subjects
Eligible women were aged between 18 and 35 years, pre-
menopausal, and had a body mass index (BMI) between 18
and 30 kg/m2. Exclusion criteria included an endocrine
disease, neurological problems, a cardiovascular condition,
hypertension, abnormal liver or renal function, and a his-
tory of a hormone-dependent malignancy. Women taking
medications that interfere with the metabolism of sex ste-
roids (e.g., oral contraceptives containing anti-androgens or
(anti)androgenic progestogens), or who used serotonergic
drugs or who had used testosterone therapy within
6 months before study entry were also excluded.
Women were recruited and enrolled from advertise-
ments, and via a database of a contract research organi-
zation (QPS in the Netherlands). Recruitment started in
June 2012 and the study was ended in November 2012. To
determine eligibility, participants were screened approxi-
mately 4 weeks prior to study entry. In addition to an
assessment of medical history, all subjects received a
physical examination including a 12-lead electrocardio-
gram, standard biochemistry, serology, and hematological
laboratory tests. Blood samples for determination of
baseline levels of total testosterone, sex hormone-binding
globulin (SHBG), albumin, thyroid-stimulating hormone
(TSH), follicle-stimulating hormone (FSH) and estrogen
were collected at the screening visit. A urine pregnancy test
was applied to all women.
Thirteen healthy young women participated after pro-
viding written informed consent. This study was approved
by the local medical ethics committee (Stichting BEBO,
Assen, the Netherlands) and carried out in agreement with
the International Conference on Harmonisation-Good
Clinical Practice (ICH-GCP).
2.2 Study Design
This was a single-center, investigator-blind, randomized,
cross-over controlled study investigating two different
modes of administration of a combination of testosterone
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and buspirone. The first mode (F1) consisted of the
administration of a sublingual solution containing testos-
terone (0.5 mg) complexed with cyclodextrin, followed
2.5 hours later by an orally administered tablet containing
10 mg buspirone hydrochloride in a gelatin capsule. The
second mode of administration (F2) consisted of an inno-
vative fixed-combination tablet with an inner-core com-
ponent of 10 mg buspirone hydrochloride coated with a
polymeric ethylcellulose-based time-delay coating and an
outer coating containing 0.5 mg testosterone complexed
with hydroxypropyl-b cyclodextrin.
All 13 subjects received the investigational drug for-
mulation in random order. Wash-out between treatments
was at least 7 days. Subjects had serial blood samples
drawn via an intravenous catheter. Pharmacokinetic
parameters were monitored at baseline (-10 min) and (at
5, 10, 15, 20, 25, 30, 60, 90, 120, 135, 145, 165, 180, 195,
210, 225, 240, 270, 300, 330, 360, 390, 450, 570, 690, 810,
930, 1,590 min) after dosing.
Measurement of total testosterone, free testosterone, and
dihydrotestosterone were performed at -10, 5, 10, 15, 20,
25, 30, 60, 90, 120, 145, 180, 240 and 1,590 minutes after
dosing; buspirone and metabolite 1-(2-pyrimidinyl)-piper-
azine at -10, 10, 30, 60, 90, 120, 135, 145, 165, 180, 195,
210, 225, 240, 270, 300, 330, 360, 390, 450, 570, 690, 810,
930, 1,590 minutes after dosing.
For each admission period, subjects were instructed to
come to the study site on the evening prior to dose
administration where vital signs were checked (including
ECG) and urine drug test, pregnancy test, and alcohol
breath analysis were performed. During the admission
period, the subjects received low calorie meals on site and
decaffeinated coffee and tea to minimize the influence on
pharmacokinetic parameters. Drug, alcohol, and preg-
nancy tests were performed prior to experimental
sessions.
2.3 Medication and Dosing
The combination tablet is a menthol-flavored white tablet
of 9 mm in diameter for sublingual administration fol-
lowed by oral administration. The quickly dissolving outer
coating, applied by film coating the tablet, delivers cyclo-
dextrin-complexed testosterone (0.5 mg) sublingually, and
the time-delayed-release core delivers buspirone (10 mg)
2.5 hours later. The outer coating comprises testosterone,
excipients, and a menthol flavor to guide the disappearance
of the coating. The testosterone coating is designed to fully
dissolve and to obtain a fast and complete absorption via
the mucosal membranes under the tongue. The time-
delayed-release core containing the buspirone has been
designed on the basis of in-vitro release studies of US
Pharmacopeia (USP) II and III, to release the buspirone in a
pulsatile manner, approximately 2.5 hours after oral
administration. This method of release is accomplished
through the use of a polymer coating of ethylcellulose
which allows for a slow permeation of water in a pH-
independent manner. At the predetermined time, the
polymer coating ruptures at the edge of the tablet. The
complete disintegrated core of the inner tablet is released
immediately, after which there is no delay for the disso-
lution of the buspirone in the surrounding fluid.
The two formulations were administered by a trained
research associate and controlled by a second research
associate.
For the testosterone component of F1, a 1 mg/mL tes-
tosterone cyclodextrin complex solution was used; the
solution was administered with a micropipette (e.g., Ep-
pendorf) into the subject’s mouth under the tongue, and the
subjects were instructed to keep the solution sublingually
for 60 seconds while moving the tongue slightly to opti-
mize absorption. After 60 seconds the subject was
instructed to swallow the solution. The buspirone compo-
nent of F1 was administered orally, as an encapsulated
tablet with a glass of water (approximately 200 mL)
150 minutes later.
For F2, the subject was instructed to keep the tablet in
the mouth sublingually for 90 seconds, while moving the
tongue slightly to optimize absorption. The amount of time
that the tablet was in the mouth was timed so that the tablet
was swallowed at exactly the right time. After 90 seconds,
the subject was instructed to swallow the tablet as a whole,
without chewing or otherwise disrupting the dosage form.
If necessary, the subject could take a glass of water to
enable swallowing.
2.4 Hormone Assays
The assay used for the determination of total testosterone
and dihydrotestosterone was High Performance Liquid
Chromatography with Mass Spectrometric detection
(HPLC–MS/MS) (API 4000, Applied Biosystems, MDS
SCIEX). Free testosterone was determined in plasma
through ultra-filtration followed by HPLC–MS/MS. The
method was validated with a lower limit of quantification
(LLOQ) of 1.00 pg/mL for free testosterone with an intra-
assay coefficient of variation (CV) of 5.2 % and an inter-
assay CV of 12.6 %. The LLOQ for testosterone was
0.02 ng/mL with an intra-assay CV of 11.0 % and an inter-
assay CV of 12.8 %. The LLOQ for dihydrotestosterone
was 0.02 ng/mL with an intra-assay CV of 23.6 % and an
inter-assay CV of 29.5 %. The HPLC–MS/MS assay is a
reliable and sensitive method for the analysis of free tes-
tosterone and overcomes the known limitations of direct
immunoassays in measurement of testosterone values in
the lower range [24, 25].
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2.5 Buspirone and 1-(2-Pyrimidinyl)-Piperazine Assay
The analytes buspirone and its major metabolite 1-(2-
pyrimidinyl)-piperazine were determined in plasma by
HPLC–MS/MS. The method was validated with a LLOQ
of 0.01 ng/mL for buspirone with an intra-assay CV of
12.9 % and an inter-assay CV of 7.2 %. The LLOQ for
1-(2-pyrimidinyl)-piperazine was 0.20 ng/mL with an
intra-assay CV of 9.4 % and an inter-assay CV of 4.7 %.
2.6 Statistical Analysis
The pharmacokinetic parameters were analyzed using the
Watson 7.2 Bioanalytical LIMS software (Thermo Electron
Corporation, Philadelphia, USA).
Pharmacokinetic parameters including AUC, Cmax, Tmax
and T were calculated based on actual and baseline cor-
rected individual concentration–time curves. AUCs were
estimated using the linear trapezoidal rule. Cmax and Tmax
were taken from the measured values. T was calculated
from the unweighted linear regression of the log trans-
formed data determined at the elimination phase of the
pharmacokinetic profile of each subject.
The AUC0–1,590 was determined as the area under the
concentration versus time curve from the first time point
to the last time point with measurable drug concentra-
tion with a linear/log-linear trapezoidal model. The
AUC0–? was calculated from the AUC0–1,590 by the
addition of a constant (Cp/kz), where Cp is the last
observed quantifiable concentration and kz is elimina-
tion rate constant. This was performed by dividing the
Cp by kz determined using linear regression of Cp
versus time data (standard extrapolation technique). The
elimination rate constant and the corresponding elimi-
nation half-life was estimated by log-linear least squares
regression of the terminal part of the plasma concen-
tration versus time curve. Absorption lag time (Tlag) is
determined as the first time point with a measurable
concentration in plasma.
The demographic baseline levels of total and free tes-
tosterone, dihydrotestosterone, SHBG, and albumin were
calculated by taking the mean of F1 and F2. For the
baseline corrected pharmacokinetic parameters, the raw
data of each subject was taken as baseline. Dependent on
distribution of normality, paired-samples t tests were used
for the difference between the F1 and F2 pharmacokinetic
parameters for the subjects of whom F1 and F2 data was
obtained (n = 12). For all analyses a (two-sided) p value
\0.05 was considered statistically significant. Statistical
analyses were conducted with SPSS 19.0 (IBM SPSS
Statistics for Windows, Version 19.0. Armonk, NY: IBM
Corp).
3 Results
The baseline characteristics and hormone levels of the 13
study participants are outlined in Table 1. Because one
subject discontinued after F1 dose, an additional subject
was included into the study in order to have F1 and F2 data
from 12 subjects. Therefore, 13 subjects were included in
F1 and 12 subjects were included in F2. Table 1 shows the
baseline demographics of the 13 study participants, all
subjects were Caucasian and the mean age was 25.8 years.
Baseline levels (measured at screening) of testosterone,
SHBG, and albumin were all in the normal female range.
3.1 Pharmacokinetic Results
3.1.1 Testosterone, Free Testosterone
and Dihydrotestosterone
Pharmacokinetic results of the two administrations show
that from both products, testosterone was rapidly absorbed
with a total testosterone Tmax between 12 and 16 minutes
(0.201–0.256 h) and a half-life between 36 and 44 minutes
(0.598–0.726 h). Free testosterone reached the maximum
concentration within 12–15 minutes (0.194–0.250 h) with
a half-life between 40 and 48 min (0.674–0.798 h). Cmax is
significantly higher for total (p = 0.003) and free testos-
terone (p = 0.003) after F2 administration compared with
F1 dosing. Furthermore, it is observed that the average
AUC with F2 dosing is significantly higher for free
Table 1 Baseline and clinical characteristics of the participants
Characteristic Value (n = 13)
Age (years) 25.8 ± 4.9
Race
Caucasian 13
BMI (kg/m2) 22.9 ± 2.1
Contraceptive
Hormonal 12
Combined oral contraceptive pill 8
IUD (levonorgestrel) 3
Vaginal ring (progestin and estrogen) 1
Non-hormonal 1
Total testosterone (ng/mL) 0.26 ± 0.1
SHBG (nmol/L) 92 ± 80
Albumin (g/L) 41.5 ± 2.8
Baseline levels of total testosterone, SHBG and albumin were mea-
sured at the screening visit
The values are mean ± SD. To convert total testosterone to nano-
moles per liter, multiply by 3.467
BMI body mass index, IUD intrauterine device, SHBG sex hormone-
binding globulin
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testosterone (p = 0.018) and not statistically significant for
total testosterone (p = 0.078) compared with the F1 dos-
ing. The pharmacokinetic parameters of total and free
testosterone and dihydrotestosterone after the different
modes of administration are summarized in Table 2.
The mean concentrations of testosterone, free testoster-
one, and dihydrotestosterone measured after sublingual
administration of a single dose of testosterone (0.50 mg)
after F1 and F2 administration are shown in the Figs. 1, 2
and 3.
3.1.2 Buspirone and 1-(2-Pyrimidinyl)-Piperazine
Pharmacokinetic results of the two administrations show
that from both products, buspirone was absorbed with a
Tmax between 3.69 and 3.95 hours and a half-life between
6.03 and 7.12 hours. Buspirone Tlag (median) was
approximately 3 hours after F1 and approximately 3 hours
and 20 minutes after F2 administration. Since for F1 the
encapsulated tablet was taken after 150 minutes (2.5 h),
the in vivo dissolution and absorption of buspirone took
30 minutes. The in vivo lag time for F2 was 200 –
30 = 170 minutes, which was well in line with in vitro
observations of the tablet. 1-(2-pyrimidinyl)-piperazine
reached the maximum concentration after approximately
4 hours (4.02–4.40 h) with a half-life between 4.84 and
4.86 hours. Cmax and AUC were not significantly different
between the F1 and F2 administration for buspirone as well
as 1-(2-pyrimidinyl)-piperazine.
Table 2 Pharmacokinetic parameters for total testosterone, free testosterone, and dihydrotestosterone after F1 and F2 administration
Dosing Cmax (ng/mL) Tmax (h) AUC(0–1,590) (ng*h/mL) T (h)
F1 total testosterone (ng/mL) 5.65 ± 2.35 0.256 ± 0.063 6.41 ± 2.23 0.726 ± 0.165
F2 total testosterone (ng/mL) 7.84 ± 3.69* 0.201 ± 0.043 8.10 ± 2.49 0.598 ± 0.080
F1 free testosterone (pg/mL) 36.2 ± 14.9 0.250 ± 0.083 35.1 ± 18.8 0.674 ± 0.187
F2 free testosterone (pg/mL) 52.4 ± 20.8* 0.194 ± 0.054 55.5 ± 31.1* 0.798 ± 0.247
F1 dihydrotestosterone (ng/mL) 0.519 ± 0.222 0.410 ± 0.105 1.39 ± 0.87 1.14 ± 0.49
F2 dihydrotestosterone (ng/mL) 0.578 ± 0.245 0.451 ± 0.066 1.17 ± 0.47 0.850 ± 0.336
For all calculations, the predose concentration is subtracted from the determined concentration after dosing. The values are mean ± SD. The
means of F1 are calculated with the data of 13 women and the means of F2 are based on the data of 12 women
To convert total testosterone to nanomoles per liter, multiply by 3.467
AUC area under the curve, Cmax maximum concentration, Tmax time to maximum concentration, T half-life
* p \ 0.05, value at F2 is significantly different from F1
Fig. 1 Mean total testosterone plasma concentration–time profile Fig. 2 Mean free testosterone plasma concentration–time profile
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The pharmacokinetic parameters of buspirone and its
primary metabolite 1-(2-pyrimidinyl)-piperazine after the
F1 and F2 modes of administration are summarized in
Table 3.
The mean concentration–time profiles of buspirone and
1-(2-pyrimidinyl)-piperazine measured after oral adminis-
tration of a single dose of buspirone (10 mg) using the F1
and F2 modes of administration are shown in Figs. 4 and 5.
The two formulations were well tolerated.
4 Discussion
Our results demonstrate that sublingual administration of
testosterone in both formulations was followed by a very
quick and steep increase of total and free testosterone
levels; with peak levels reached between 10 and 20 min-
utes, which is in line with our previous studies [9, 26].
Serum levels of total and free testosterone rapidly declined
to reach baseline levels by approximately 2.5 hours.
The total testosterone Cmax following administration of
0.50 mg sublingual testosterone after the liquid dosing
regimen showed consistency with the reported Cmax of Tu-
iten et al. and van Rooij et al. [9, 26]; however, the Cmax of
total and free testosterone after administration of the tablet is
higher. This is also reflected by the AUC for total and free
testosterone after administration of the tablet compared with
the liquid dosing, meaning very fast absorption from the
solid polymeric matrix. Since there is no time delay or dif-
ference in absorption for the two formulations, the in vivo
dissolution of testosterone from the tablet coating is not the
rate-limiting step in the absorption process, which indicates
that the driving force for dissolution in the saliva is high. It is
surprising that the bioavailability of testosterone from the
tablet is higher than from the liquid, since one would expect
it to be the other way around, and certainly for anFig. 3 Mean dihydrotestosterone plasma concentration–time profiles







Tlag (h) T (h)
F1 buspirone (ng/mL) 3.95 ± 4.38 3.69 ± 0.54 7.63 ± 8.07 8.02 ± 8.57 2.96 ± 0.14 6.03 ± 2.27
F2 buspirone (ng/mL) 2.16 ± 2.55 3.95 ± 1.82 5.14 ± 5.08 5.56 ± 5.24 3.33 ± 0.82 7.12 ± 2.33
F1 1-(2-pyrimidinyl)-piperazine
(ng/mL)
4.35 ± 1.65 4.02 ± 0.68 25.4 ± 14.60 27.4 ± 17.8 3.27 ± 0.33 4.84 ± 2.11
F2 1-(2-pyrimidinyl)-piperazine
(ng/mL)
3.99 ± 1.71 4.40 ± 2.27 21.6 ± 6.7 22.7 ± 7.4 3.58 ± 1.32 4.86 ± 1.66
The values are mean ± SD. The means of F1 are calculated with the data of 13 women and the means of F2 are based on the data of 12 women
AUC area under the curve, Cmax maximum concentration, Tlag absorption lag time, Tmax time to maximum concentration, T half-life
Fig. 4 Mean buspirone plasma concentration–time profile
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intrinsically insoluble compound such as testosterone. On
the other hand, it should be taken into account that a small
amount of the liquid testosterone (0.5 ml) may leak away to
the esophagus and stomach which could explain the lower
bioavailability of this dosage form compared with the
combination tablet. In a previous study of van Rooij et al.,
three different doses of the liquid testosterone were inves-
tigated (0.25, 0.50, and 0.75 mg) and it was observed that the
lowest testosterone dose (0.25 mg) had the highest bio-
availability [26]. In that study, the 0.50 mg of sublingual
testosterone solution had a relative availability to the lowest
dose of 69 %. The AUC of the lowest dose was dose cor-
rected equivalent to a 0.3 mg single pulmonal testosterone
dose described by Davison and colleagues [27]. Due to the
properties of testosterone, the low dose, and the large surface
area of the lungs, it was anticipated that this was a near
100 % bioavailability, resulting in an approximate 70 %
bioavailability for the 0.5 mg liquid sublingual dose. And
since the new combination tablet with the coating of tes-
tosterone has both a higher Cmax and AUC, we assume that
the absolute bioavailability of this tablet is above 70 and
probably close to 80 %.
The metabolite dihydrotestosterone peak levels were
reached within 30 minutes and levels returned to baseline
levels within 4 hours, which is also consistent with our
previous pharmacokinetic study [26].
Due to the high first-pass effect, the variability between
the subjects for the buspirone levels was as expected very
high. The Tlag time and the Tmax for both buspirone and its
metabolite 1-(2-pyrimidinyl)-piperazine were comparable
for both formulations. This indicates that the in vivo rup-
ture time of the tablet is within the set specification of
120–240 minutes (average 150 min).
Although the Cmax for buspirone was not significantly
different between the two formulations, the average Cmax
was somewhat lower for the combination tablet (F2)
compared with the encapsulated tablet (F1) taken after
150 minutes. The encapsulated gelatin capsule of F1 is
probably absorbed in the stomach, while the combination
tablet is absorbed at a more distal location in the gastro-
intestinal tract (in the small intestines). Since the combi-
nation tablet will release its drug load after a 150-minute
longer travel through the gastrointestinal tract, this could
have influenced the Cmax for buspirone. However, based on
the AUC of the main first-pass metabolite of buspirone,
there does not seem to be a significant incomplete
absorption of the buspirone, but rather a more extensive
first-pass effect with the tablet that resides longer and
further in the gastrointestinal tract.
5 Conclusion
In conclusion, there was adequate absorption of both testos-
terone and buspirone and an adequate time delay for the
release of buspirone after administration of the combination
tablet, which is a well tolerated, convenient and suitable for-
mulation for Lybridos administration in a daily practical set-
ting. All subsequent clinical studies, including dose-finding
studies, will be done with this innovative tablet formulation.
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